Answers are grounded in this paper and cite their sources.
Objective: While schizophrenia usually has an persistent recurring sequence, any kind of pharmaceutical advancement planned for attenuation of positive and negative symptoms may aid to reduce its unrelenting chronic sequence. Risperidone and olanzapine, as Second Generation Antipsychotic agents (SGAs), have been developed to come across this necessity. In the current assessment, effectiveness and safety of these two atypical antipsychotics has been compared with each other.
No takes yet. Share an insight, caveat, or question.
Shafti et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: